Taxpayers spent $74.5 million to help develop the prostate cancer-fighting drug Xtandi, but its sky-high sticker price is limiting access to patients and siphoning money away from Medicaid, according ...

New Diagnostics, AI Breakthroughs, and Next-Gen Therapies Are Transforming the Oncology Market. The oncology sector is experiencing <stron ...

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

Five-year data from the POETYK PSO long-term extension trial confirm the sustained efficacy and safety of Sotyktu ...